Navigation Links
New research effort into causes of chronic fatigue syndrome
Date:9/27/2011

September 27, 2011 --The Chronic Fatigue Initiative (CFI) a new privately funded research directive focused on chronic fatigue syndrome announced a substantial grant to a Columbia University research team to investigate the role of pathogens in causing chronic fatigue syndrome. The pathogen discovery and pathogenesis program will be led by Drs. Ian Lipkin and Mady Hornig of the Center for Infection and Immunity.

Chronic fatigue syndrome is a condition believed to affect about 1million Americans. It is characterized by symptoms similar to those of common viral infections and can include muscle aches, headache and extreme fatigue. Its cause is unknown, and currently there is no cure.

Established by a donation of more than $10 million from the Hutchins Family Foundation, the Chronic Fatigue Initiative will bring together medical experts from the world's leading research institutions, including Columbia, Harvard, Stanford and Duke Universities. The Initiative's initial phase of funding includes support for pathogenesis research at the Center for Infection and Immunity, and for NewYork-Presbyterian Hospital/Columbia University Medical Center, where it will establish the Hutchins Family Fellowship in Infectious Disease under the direction of Dr. Scott Hammer, professor of epidemiology and chief of the Division of Infectious Diseases at NewYork-Presbyterian/Columbia.

"Dr. Hornig was the prime mover in designing the research plan and will be shepherding the CFI's research at the Center for Infection and Immunity," said Dr. Lipkin, the director of CII.

Dr. Hornig, an associate professor of epidemiology at the Mailman School of Public Health and director of Translational Research at CII, will direct research on biomarkers and pathogen discovery for the Chronic Fatigue Initiative. The research will focus on characterizing the causes of this enigmatic disorder.

Scientists will examine samples from 200 patients and controls using state-of-the-art molecular techniques pioneered at CII. Patients will be recruited across the country from five clinical sites that specialize in chronic fatigue syndrome.

During the first part of the project, they will screen for already known pathogens thought to be associated with the disease. Then they will use unbiased genetic sequencing to help them identify any novel pathogens. CII scientists will also look at patients' host response profiles the immune molecule and antibody signatures in their peripheral blood samples. This will enable researchers to get a comprehensive picture of what is happening in individual patients in relation to pathogens to which they may have been exposed and could lead to the identification of biomarkers for CFS.

Drs. Lipkin and Hornig will also collaborate with Dr. Scott M. Hammer and the inaugural Hutchins Family Fellow for Infectious Disease at NewYork-Presbyterian/Columbia Dr. Claire Gordon.

"This is a truly exciting opportunity to understand the causes of this often neglected disorder," said Dr. Hornig. "We hope our findings will lead to better diagnoses and the development of an effective treatment."


'/>"/>

Contact: Stephanie Berger
sb2247@columbia.edu
212-305-4372
Columbia University's Mailman School of Public Health
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: